1.17 USD
-0.02 (-1.68%)
Overall AEON gets a fundamental rating of 1 out of 10. We evaluated AEON against 0 industry peers in the Unkown industry. Both the profitability and financial health of AEON have multiple concerns. AEON has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year AEON has reported negative net income.
- AEON had a negative operating cash flow in the past year.
- In the past 5 years AEON reported 4 times negative net income.
- In the past 5 years AEON always reported negative operating cash flow.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.03% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-1589.97%
ROA(5y)-1126.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for AEON so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- AEON has more shares outstanding than it did 1 year ago.
- AEON has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, AEON has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -53.59, we must say that AEON is in the distress zone and has some risk of bankruptcy.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -53.59 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.12 indicates that AEON should not have too much problems paying its short term obligations.
- AEON has a Quick Ratio of 1.12. This is a normal value and indicates that AEON is financially healthy and should not expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 99.01% over the past year.
- The Earnings Per Share has been growing by 56.13% on average over the past years. This is a very strong growth
EPS 1Y (TTM)99.01%
EPS 3YN/A
EPS 5Y56.13%
EPS Q2Q%95.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, AEON will show a very negative growth in Earnings Per Share. The EPS will decrease by -49.88% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-100.97%
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%
EPS Next 5Y-49.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- AEON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year AEON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- AEON's earnings are expected to decrease with -26.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%
5. Dividend
5.1 Amount
- No dividends for AEON!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AEON BIOPHARMA INC / AEON FAQ
Can you provide the ChartMill fundamental rating for AEON BIOPHARMA INC?
ChartMill assigns a fundamental rating of 1 / 10 to AEON.
What is the valuation status of AEON BIOPHARMA INC (AEON) stock?
ChartMill assigns a valuation rating of 0 / 10 to AEON BIOPHARMA INC (AEON). This can be considered as Overvalued.
What is the profitability of AEON stock?
AEON BIOPHARMA INC (AEON) has a profitability rating of 0 / 10.